Is Wegovy Worth It for Weight Loss? Here's What the Evidence Actually Shows

The biggest misconception: that clinical-trial results translate directly to everyone

The most common misreading our prescribers encounter (a question that comes up most weeks) is whether the 15% average weight loss from the STEP 1 trial is a figure you can simply expect for yourself. It isn't quite that straightforward. That average is drawn from 1,961 adults with obesity or overweight and at least one weight-related condition, all of whom also followed a reduced-calorie diet and increased their physical activity. The medicine worked within a structured programme, not in isolation.

Some participants lost considerably more than 15%; others lost less. A meaningful minority did not reach the 5% threshold that NICE uses as a marker of adequate response after six months on the maintenance dose, and in those cases, continuing is reviewed. So "worth it" is not a universal yes or no. It is a probability question shaped by your starting point, how well your body responds, and whether the wider lifestyle changes are sustainable for you.

What the evidence does show clearly is that semaglutide produced statistically significant, clinically meaningful weight loss compared with placebo across thousands of participants. That is a strong signal. The STEP 1 trial in the New England Journal of Medicine remains one of the most cited pieces of evidence in modern obesity medicine.

Why Wegovy works, and why it stops working if you stop taking it

Semaglutide mimics a gut hormone called GLP-1, which signals fullness to the brain, slows how quickly the stomach empties, and reduces appetite. You can read a fuller explanation of the mechanism on our how Wegovy works for weight loss page. The practical upshot is that most people find food feels less urgent, portion sizes fall naturally rather than through willpower alone.

The flip side is also real. Weight tends to return when treatment stops, because the hormonal signals that suppressed appetite go with it. Several trials following participants after discontinuation have reported significant regain within a year. This does not make the medicine "not worth it", but it does mean that treatment is typically long-term, and stopping without a plan is rarely advisable. Your prescriber should discuss a maintenance or exit strategy as part of ongoing care.

For context on what a realistic first month looks like before making a longer commitment, the question of whether one month of Wegovy is worth it is explored separately, with honest expectations about the early titration phase.

Who Wegovy is actually licensed for, and where cost fits the picture

In the UK, Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as hypertension, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under NICE's appraisal of semaglutide (TA875). Pregnancy, breastfeeding, and trying to conceive are situations where Wegovy is not recommended; the same applies to anyone under 18. A prescriber assesses the full picture, BMI alone does not settle the question.

Cost is a fair part of the "worth it" calculation. Private treatment prices have risen since Eli Lilly's list-price changes in late 2025 reshaped the wider market; Wegovy private pricing typically sits in a similar range to other GLP-1 options by dose. If you want to understand how that pricing is structured and what a legitimate prescription service should include, the Wegovy for weight loss overview covers the cost context without burying the numbers. The short version: any legitimate price should include clinical assessment, not just the medicine.

On the NHS, Wegovy is available through specialist weight management services under TA875, though waiting lists are commonly long and criteria are specific. Private treatment through a regulated pharmacy is the alternative for people who are clinically suitable but cannot access NHS provision.

Putting it together: what "worth it" actually means for a prescription medicine

Wegovy is a prescription-only medicine, which means the question of worth is partly answered by the clinical assessment itself. If a prescriber determines that you are a suitable candidate, the evidence base is strong. The semaglutide overview and the broader Wegovy information page both go deeper on what the medicine is and how it compares to other options. For men specifically, Wegovy for weight loss in men addresses some of the questions that come up around body composition and expectations.

Price is the wrong test for a prescription medicine. The right questions are whether you have a clinical need, whether you can access a genuine, supervised supply chain, and whether your expectations are grounded in what the trials actually found. If those answers line up, the evidence suggests Wegovy can produce meaningful, sustained weight loss for many adults, provided treatment continues alongside realistic lifestyle changes and regular clinical oversight.

If you're ready to find out whether you're eligible, check your eligibility with our prescribers, it's free, there's no obligation, and a real clinician reviews your answers the same day.